Press Releases

Date Title and Summary
Toggle Summary Capnia Provides Corporate Update and Reports First Quarter 2017 Financial Results
Completed merger with Essentialis, Inc. and concurrent financing of $10 million New company name, Soleno Therapeutics, Inc. , to reflect new strategic focus on rare disease therapeutics; stock to trade under NASDAQ ticker symbol “SLNO” Scientific advice being obtained from the U.S.
Toggle Summary Capnia Reports Fourth Quarter and Full Year 2016 Financial Results
REDWOOD CITY, Calif. , March 15, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today announced financial results for the fourth quarter and twelve months ended December 31, 2016 .
Toggle Summary Capnia Completes Merger with Essentialis Creating Rare Disease Therapeutics Company
Lead Clinical Asset Entering Phase II/III Development in 2017 for the  Treatment of Prader-Willi Syndrome Raises $10 Million in Concurrent Financing; Cash Runway Through Key Milestones REDWOOD CITY, Calif. , March 08, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc.
Toggle Summary Capnia to Present at the 19th Annual BIO CEO & Investor Conference
REDWOOD CITY, Calif. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar , M.D., Chief Executive
Toggle Summary Capnia and Essentialis Announce Merger to Create Rare Disease Therapeutics Company
Combined Company to Focus on Advancing Novel, Late-Stage Asset for the Treatment of Prader-Willi Syndrome, a Devastating, Orphan Disease  Enrollment in a Phase II/III Clinical Trial Expected to Begin in Second Half of 2017 $8 Million Concurrent Financing; Sufficient to Fund Development Plan Through
Toggle Summary Capnia Reports Third Quarter 2016 Financial Results
REDWOOD CITY, Calif. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced financial results for the third quarter ended
Toggle Summary Capnia to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar , M.D., Chief Executive
Toggle Summary Capnia Reports Second Quarter 2016 Financial Results
Strong Consumer Feedback from Pilot Serenz Sales in the UK REDWOOD CITY, Calif. , Aug. 12, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today
Toggle Summary Capnia Announces Private Placement of Up to $13.8 Million of Convertible Preferred Stock
REDWOOD CITY, Calif. , June 29, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that it has entered into an agreement with a
Toggle Summary Capnia Expands Commercial Launch of Serenz® Allergy Relief to Ireland
- Pilot Program to Include 25 Community Pharmacies - REDWOOD CITY, Calif. , June 15, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today